Dolutegravir

Drug Profile

Dolutegravir

Alternative Names: '572; 1349572; Dolutegravir sodium; DTG; GSK-1349572; S-349572; S/GSK 1349572; Tivicay

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shionogi-GlaxoSmithKline Pharmaceuticals
  • Developer Bellvitge University Hospital; GlaxoSmithKline; INSERM; National Institute of Allergy and Infectious Diseases; Shionogi-GlaxoSmithKline Pharmaceuticals; University of Liverpool; ViiV Healthcare
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Oxazines; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections
  • Phase III HIV infections

Most Recent Events

  • 01 Sep 2017 Viiv Healthcare completes a phase III trial in HIV-1 infections (Combination therapy) in USA (NCT02263326)
  • 25 Jul 2017 Positive interim efficacy data from the phase III DAWNING trial in HIV-1 infections released by ViiV Healthcare
  • 23 Jun 2017 ViiV Healthcare and GlaxoSmithKline completes a phase I trial for HIV-1 infections (In volunteers) (NCT03095638)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top